CoronaVac’s Overall Efficacy in Brazil Measured at 50.4%

Caixin Global | Jan 13, 2021 at 2:13 PM
  • — Brazil officials said the CoronaVac vaccine developed in partnership with Sinovac Biotech Ltd. was 50.38% effective in preventing coronavirus cases, a number that meets the threshold required by global regulators for approval but that’s well below the 78% figure announced last week.
  • When very mild cases among the 13,000 volunteers are included, the figure is 50.4% — 167 infected in the placebo arm, and 85 in the vaccine arm.
  • The efficacy rate is key for officials to determine how much of the population needs to be immunized in order to halt the spread of the virus.